NFE2L2 and Parkinson disease: Chemicals that activate the Nrf2/HO-1 pathway have demonstrated therapeutic effects against PD models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 1-Methyl-4-phenylpyridinium (MPP+), and other agents [70,71].